WW International (WW) Earnings Date & Reports

Key Takeaways

• WW International is expected to report its third-quarter 2026 results in late October or early November, with the exact date yet to be confirmed by the company.
• Analyst consensus points to roughly $0.62 per share in earnings on revenue near $152 million, down from the prior-year period.
• The core story remains a subscriber mix shift: a shrinking Core behavioral base versus fast-growing Clinical and Core+ tiers.
• Management reaffirmed full-year 2026 guidance in Q2, calling for revenue of $620–$635 million and adjusted EBITDA of $105–$115 million.
• Investors will focus on clinical subscriber momentum, average revenue per user (ARPU), and margin stability.

Earnings Context and Why It Matters

WW International, the company behind the Weight Watchers brand, is in the middle of a multiyear transformation toward a business built around clinical weight-loss services and higher-value behavioral memberships. After emerging from a 2025 Chapter 11 financial reorganization, the company has prioritized profitability, cash generation, and a rebalanced portfolio for the GLP-1 (glucagon-like peptide-1) medication era. Its quarterly results now serve as a progress report on whether that pivot is working. For investors, this report matters because it tests whether growth in Clinical and Core+ subscribers can offset a secular decline in the legacy Core tier, and whether the company can hold its near-record margins while revenue continues to contract.

Earnings Expectations

Heading into the third-quarter 2026 report, sell-side analysts project earnings of approximately $0.62 per share on revenue near $152 million, according to consensus data. That compares with a second quarter in which WW posted revenue of $162.3 million, a 14.2% year-over-year decline, and a GAAP (generally accepted accounting principles) profit of $1.41 per share that was heavily influenced by a one-time gain on debt extinguishment.

On the guidance front, the company reaffirmed its full-year 2026 outlook in its Q2 release: revenue of $620 million to $635 million and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) of $105 million to $115 million. Adjusted EBITDA is a key metric here because it strips out non-cash charges tied to the company's fresh start accounting following its reorganization. Investors will be watching whether the third-quarter print keeps the company on track to meet those targets.

Key operating metrics to monitor include end-of-period subscribers, ARPU, and the split between behavioral and clinical subscription revenue. In Q2, clinical subscribers reached 197,000, up 55.7% year over year, while the Core+ tier hit 541,000 subscribers, up 13.9%. Those gains have been partly offset by a shrinking Core base, which has kept overall revenue in decline.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending stocks, breakout candidates, and emerging opportunities far more efficiently than manual screening, making it a useful companion when preparing for events like a quarterly earnings release. Explore the AI Screener to build a watchlist tailored to your own criteria.

Market Reaction and Investor Sentiment

Sentiment around WW remains cautious. The stock has struggled as investors weigh persistent revenue declines against encouraging signs in the clinical and Core+ segments. Following the second-quarter report, the stock traded modestly lower despite a headline earnings beat, suggesting the market wanted clearer evidence that the subscriber mix shift is accelerating. Heading into the third-quarter report, key risk factors include further erosion of the Core behavioral base, competitive pressure in the weight-loss medication market, and any signs that clinical subscriber growth is stalling. Conversely, a strong clinical print or an upward revision to guidance could improve sentiment.

Forward Outlook and Key Factors to Monitor

Looking past the third-quarter report, the central question is whether WW can convert its clinical momentum into sustainable, profitable growth. Clinical subscriptions generate far higher ARPU than the Core behavioral tier, so continued growth there should support revenue per subscriber even as the total subscriber count shrinks.

Margin and cost discipline will be another area to watch. The company has held adjusted gross margin near record levels despite a greater revenue mix from clinical services, which carry higher staffing costs. Investors will want to see that efficiency persist as the clinical business scales.

Liquidity and debt reduction also remain in focus. WW has been prepaying its term loan and reducing interest expense, which strengthens the balance sheet but consumes cash. Any commentary on cash generation or additional debt paydown will be relevant.

Finally, watch for updates on strategic initiatives such as expanded medication-access channels and partnerships, which could influence subscriber recruitment heading into the seasonally important start of the new year. These factors, taken together, will shape how investors assess the company's turnaround trajectory through 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations